Answers are grounded in this paper and cite their sources.
Despite the lack of randomized controlled trials PM for sarcomatous disease is a reasonable therapeutic option with acceptable survival in a selected patient population. In sarcoma patients with a shorter interoperative interval and G3 tumour, shorter survival after PM can be expected.
No takes yet. Share an insight, caveat, or question.
Dudek et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: